Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 356

1.

An inhibitor of the pleckstrin homology domain of CNK1 selectively blocks the growth of mutant KRAS cells and tumors.

Indarte M, Puentes R, Maruggi M, Ihle NT, Grandjean G, Scott M, Ahmed Z, Meuillet EJ, Zhang S, Lemos R, Du-Cuny L, Layng FIAL, Correa RG, Bankston LA, Liddington RC, Kirkpatrick L, Powis G.

Cancer Res. 2019 Apr 30. pii: canres.2372.2018. doi: 10.1158/0008-5472.CAN-18-2372. [Epub ahead of print]

PMID:
31040156
2.

A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase.

Cho EJ, Devkota AK, Stancu G, Edupunganti R, Powis G, Dalby KN.

SLAS Discov. 2018 Jan;23(1):1-10. doi: 10.1177/2472555217726325. Epub 2017 Aug 18.

PMID:
28820953
3.

Modeling of Patient-Derived Xenografts in Colorectal Cancer.

Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S.

Mol Cancer Ther. 2017 Jul;16(7):1435-1442. doi: 10.1158/1535-7163.MCT-16-0721. Epub 2017 May 3.

4.

Systematic approach identifies RHOA as a potential biomarker therapeutic target for Asian gastric cancer.

Chang HR, Nam S, Lee J, Kim JH, Jung HR, Park HS, Park S, Ahn YZ, Huh I, Balch C, Ku JL, Powis G, Park T, Jeong JH, Kim YH.

Oncotarget. 2016 Dec 6;7(49):81435-81451. doi: 10.18632/oncotarget.12963.

5.

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S.

Oncotarget. 2016 Jun 28;7(26):39595-39608. doi: 10.18632/oncotarget.9153.

6.

Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target.

Grandjean G, de Jong PR, James B, Koh MY, Lemos R, Kingston J, Aleshin A, Bankston LA, Miller CP, Cho EJ, Edupuganti R, Devkota A, Stancu G, Liddington RC, Dalby K, Powis G.

Cancer Res. 2016 Jul 15;76(14):4259-4269. doi: 10.1158/0008-5472.CAN-16-0401. Epub 2016 Jun 3.

7.

ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation.

de Jong PR, Taniguchi K, Harris AR, Bertin S, Takahashi N, Duong J, Campos AD, Powis G, Corr M, Karin M, Raz E.

Nat Commun. 2016 May 17;7:11551. doi: 10.1038/ncomms11551.

8.

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Kirkpatrick DL, Powis G.

Antioxid Redox Signal. 2017 Feb 20;26(6):262-273. doi: 10.1089/ars.2016.6633. Epub 2016 Apr 22. Review.

9.

Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.

Chang HR, Park HS, Ahn YZ, Nam S, Jung HR, Park S, Lee SJ, Balch C, Powis G, Ku JL, Kim YH.

BMC Cancer. 2016 Mar 9;16:200. doi: 10.1186/s12885-016-2232-2.

10.

A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice.

Koh MY, Gagea M, Sargis T, Lemos R Jr, Grandjean G, Charbono A, Bekiaris V, Sedy J, Kiriakova G, Liu X, Roberts LR, Ware C, Powis G.

Hepatology. 2016 May;63(5):1576-91. doi: 10.1002/hep.28468. Epub 2016 Mar 7.

11.

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L.

J Clin Oncol. 2015 Dec 1;33(34):4032-8. doi: 10.1200/JCO.2015.63.2497. Epub 2015 Oct 12.

12.

A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.

Nam S, Chang HR, Jung HR, Gim Y, Kim NY, Grailhe R, Seo HR, Park HS, Balch C, Lee J, Park I, Jung SY, Jeong KC, Powis G, Liang H, Lee ES, Ro J, Kim YH.

Cancer Lett. 2015 Jan 28;356(2 Pt B):880-90. doi: 10.1016/j.canlet.2014.10.038. Epub 2014 Nov 4.

13.

Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.

Koh MY, Nguyen V, Lemos R Jr, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis G.

Cancer Res. 2015 Jan 15;75(2):316-29. doi: 10.1158/0008-5472.CAN-13-2190. Epub 2014 Nov 24.

14.

HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer.

Chang HR, Nam S, Kook MC, Kim KT, Liu X, Yao H, Jung HR, Lemos R Jr, Seo HH, Park HS, Gim Y, Hong D, Huh I, Kim YW, Tan D, Liu CG, Powis G, Park T, Liang H, Kim YH.

Gut. 2016 Jan;65(1):19-32. doi: 10.1136/gutjnl-2014-307918. Epub 2014 Nov 19.

15.

The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression.

Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, Powis G.

Mol Cancer Ther. 2014 Dec;13(12):3074-85. doi: 10.1158/1535-7163.MCT-13-1001. Epub 2014 Oct 24.

16.

PATHOME: an algorithm for accurately detecting differentially expressed subpathways.

Nam S, Chang HR, Kim KT, Kook MC, Hong D, Kwon CH, Jung HR, Park HS, Powis G, Liang H, Park T, Kim YH.

Oncogene. 2014 Oct 9;33(41):4941-51. doi: 10.1038/onc.2014.80. Epub 2014 Mar 31.

17.

FXR silencing in human colon cancer by DNA methylation and KRAS signaling.

Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, Izzo J, He N, Wei C, Baladandayuthapani V, Liang H, Kopetz S, Powis G, Guo GL.

Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G48-58. doi: 10.1152/ajpgi.00234.2013. Epub 2013 Oct 31. Erratum in: Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G357.

18.

Improved synthesis of 17β-hydroxy-16α-iodo-wortmannin, 17β-hydroxy-16α-iodoPX866, and the [(131)I] analogue as useful PET tracers for PI3-kinase.

Sun D, Bhanu Prasad BA, Schuber PT Jr, Peng Z, Maxwell DS, Martin DV, Guo L, Han D, Kurihara H, Yang DJ, Gelovani JG, Powis G, Bornmann WG.

Bioorg Med Chem. 2013 Sep 1;21(17):5182-7. doi: 10.1016/j.bmc.2013.06.036. Epub 2013 Jun 27.

19.

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.

Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, Von Hoff D, Hingorani SR, Palculict TB, Izzo J, Kiriakova GM, Abdelmelek M, Bartholomeusz G, James BP, Powis G.

Cancer Res. 2013 Jun 1;73(11):3235-47. doi: 10.1158/0008-5472.CAN-11-1433. Epub 2013 Apr 30.

20.

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.

Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.

Supplemental Content

Support Center